RXI-109: Phase I started

RXi began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate RXI-109 in patients. Earlier this year, Galena Biopharma Inc. (NASDAQ:GALE, Lake Oswego, Ore.) spun out s...